Artículos del autor

solaci

Day 2

SELECT ACS: The Inclacumab seems to reduce myocardial injury post angioplasty

P-selectin is an adhesion molecule involved in the interactions between endothelial cells, platelets and leukocytes. Inclacumab is...
solaci -
Day 2

Possible benefit for patients with acute myocardial infarction but without ventricular dysfunction.

Background: To evaluate whether the administration of eplerenone 24 hours after an acute myocardial infarction (AMI) in...
solaci -
Day 2

CHAMPION PHOENIX: Cangrelor compared with clopidogrel improves efficiency without increasing bleeding in patients undergoing angioplasty

Background: Oral antiplatelet agents have a limitation in their duration of action and bioavailability. Cangrelor is an...
solaci -
Day 2

STREAM trial: It is time to check out facilitated angioplasty?

It is not clear so far whether pre-hospital fibrinolysis with early angiography could provide a clinical outcome...
solaci -
Day 2

DKCRUSH-III: Crushing versus Culotte technique for left main coronary artery

Angioplasty of the unprotected distal left main coronary artery with 2 stents presents the less favorable results...
solaci -
Day 2

PARTNER 2: Edwards SAPIEN XT is even better. Results for PARTNER II, cohort B.

In the PARTNER 1 study, patients with inoperable severe aortic stenosis treated with an aortic valve prosthesis...
solaci -
Day 2

NEXT trial looked at a non-inferiority degradable polymer stent versus a second-generation permanent polymer stent.

Previous studies of non-inferiority (SORT-OUT III and V) compared the biodegradable polymer biolimus-eluting stent (BES) with permanent...
solaci -
Day 2

PRATO ACS: Rosuvastatin reduces the incidence of contrast nephropathy in patients with acute coronary syndrome who receive early invasive strategy

The aim of this study was to determine whether patients without ST-segment elevation acute coronary syndromes who...
solaci -